From Pharmalot by Ed Silverman
Another week, another drugmaker agrees to settle off-label marketing charges brought by the federal government. This time, Novartis will pay $422.5 million for illegally promoting its Trileptal epilepsy med for unapproved uses, such as bipolar disorder and neuropathic pain... Go
here to read the full story.
UPDATE 10/1/10: More on this story at
Law.com and
The Wall Street Journal Law Blog.
UPDATE: 10/8/10: More on the story from
AboutLawsuits.com
No comments:
Post a Comment